AbCellera (ABCL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ABCL · Stock Price

USD 5.04+3.03 (+150.75%)

Market Cap: $1.6B

Historical price data

Market Cap: $1.6BPipeline: 2 drugsPatents: 1Founded: 2012Employees: ~600HQ: Vancouver, Canada

Sector Ranking#15 in AI / Machine Learning #90 in Biologics / Biosimilars

Overview

AbCellera's mission is to build a technology-driven biotech capable of repeatedly beating the odds to deliver breakthrough antibody medicines. The company achieved a landmark proof-of-concept through its partnership with Eli Lilly on bamlanivimab for COVID-19, validating its platform's speed and efficacy. Its current strategy represents a pivotal shift from a pure-play technology licensor to an integrated drug developer, leveraging its proprietary platform to build a wholly-owned pipeline of first-in-class and best-in-class assets, while maintaining a portfolio of royalty-bearing partnerships.

Endocrinology / Women's HealthImmunology & InflammationAutoimmunityOncology

Technology Platform

An integrated platform combining proprietary high-throughput microfluidics for single-cell screening, machine learning for antibody analysis and optimization, and specialized technologies for targeting complex membrane proteins like GPCRs and ion channels, enabling end-to-end antibody discovery and development.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
ABCL635 + Placebo	Vasomotor Symptoms Associated With Menopause	Phase 1/2
ABCL575 + Placebo (Normal Saline 0.9%)	Healthy Volunteers	Phase 1

Funding History

3

Total raised:$598M

IPO$483MUndisclosedDec 11, 2020

Series B$105MOrbiMedMar 15, 2020

Series A$10MDCVC BioFeb 15, 2018

Opportunities

The successful clinical development of its internal pipeline, particularly first-in-class assets like ABCL635 in the large, underserved menopausal VMS market, represents a major value-creation opportunity.

Furthermore, its validated platform and expertise in difficult target classes (GPCRs/ion channels) position it to secure high-value partnerships or out-license additional programs, providing non-dilutive funding and royalty streams.

Risk Factors

The company faces significant clinical trial risk with its lead assets, strategic execution risk in its pivot to an integrated drug developer, and financial risk associated with funding its clinical pipeline.

High competition in its chosen therapeutic areas and the need to prove its platform can repeatedly generate successful drugs beyond the singular example of bamlanivimab are additional key risks.

Competitive Landscape

As a drug developer, AbCellera competes with large pharma and biotechs in immunology (e.g., Sanofi/Regeneron's Dupixent) and women's health. As a technology platform, it competes with AI/ML-driven discovery firms like Absci and Generate:Biomedicines, and high-throughput antibody discovery providers. Its integrated platform, validated by a marketed drug, and specialized capabilities in complex targets are its key differentiators.